AUROBINDO PHARMA LTD.
NSE : AUROPHARMABSE : 524804ISIN
CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse
: Aurobindo
BSE902.65-27.25 (-2.93 % )
PREV CLOSE (Rs.) 929.90
OPEN PRICE (Rs.) 930.15
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 56317
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE902.25 -27.75 (-2.98 % )
PREV CLOSE(Rs.) 930.00
OPEN PRICE (Rs.) 935.00
BID PRICE (QTY) 902.25 (99 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2019465
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Financial ratio
Particulars | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 48.32 | 40.36 | 41.36 | 39.28 | 34.61 |
CEPS(Rs) | 65.05 | 51.71 | 50.82 | 46.49 | 41.26 |
DPS(Rs) | 3.00 | 2.50 | 2.50 | 2.50 | 2.50 |
Book NAV/Share(Rs) | 286.92 | 237.08 | 199.36 | 159.96 | 124.50 |
Tax Rate(%) | 24.31 | 23.53 | 25.27 | 24.86 | 26.28 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 10.29 | 9.86 | 22.86 | 22.76 | 22.85 |
EBIT Margin(%) | 8.60 | 8.36 | 20.10 | 20.69 | 21.49 |
Pre Tax Margin(%) | 7.95 | 7.70 | 19.62 | 20.25 | 19.65 |
PAT Margin (%) | 6.02 | 5.89 | 14.67 | 15.22 | 14.49 |
Cash Profit Margin (%) | 8.07 | 7.56 | 18.05 | 18.05 | 17.30 |
Performance Ratios | |||||
ROA(%) | 10.34 | 10.00 | 13.07 | 14.44 | 14.13 |
ROE(%) | 18.53 | 18.47 | 22.99 | 27.57 | 32.51 |
ROCE(%) | 18.80 | 17.97 | 22.72 | 24.92 | 27.35 |
Asset Turnover(x) | 1.72 | 1.70 | 0.89 | 0.95 | 0.98 |
Sales/Fixed Asset(x) | 4.12 | 4.36 | 2.44 | 2.96 | 2.79 |
Working Capital/Sales(x) | 9.40 | 12.11 | 4.70 | 5.80 | 5.69 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.24 | 0.23 | 0.41 | 0.34 | 0.36 |
Receivable days | 29.85 | 29.56 | 64.66 | 89.16 | 106.53 |
Inventory Days | 57.72 | 59.64 | 112.70 | 101.43 | 100.27 |
Payable days | 52.98 | 58.56 | 67.77 | 75.73 | 81.50 |
Valuation Parameters | |||||
PER(x) | 8.55 | 19.47 | 13.47 | 17.19 | 21.53 |
PCE(x) | 6.35 | 15.20 | 10.96 | 14.52 | 18.06 |
Price/Book(x) | 1.44 | 3.32 | 2.80 | 4.22 | 5.98 |
Yield(%) | 0.73 | 0.32 | 0.45 | 0.37 | 0.34 |
EV/Net Sales(x) | 1.17 | 2.61 | 2.20 | 2.84 | 3.47 |
EV/Core EBITDA(x) | 5.32 | 12.43 | 9.33 | 11.95 | 14.10 |
EV/EBIT(x) | 6.63 | 15.24 | 10.90 | 13.58 | 15.95 |
EV/CE(x) | 0.94 | 1.94 | 1.73 | 2.64 | 3.04 |
M Cap / Sales | 1.05 | 2.35 | 1.98 | 2.65 | 3.16 |
Growth Ratio | |||||
Net Sales Growth(%) | 18.07 | 18.83 | 10.42 | 8.08 | 13.81 |
Core EBITDA Growth(%) | 23.10 | 6.03 | 9.11 | 4.67 | 27.50 |
EBIT Growth(%) | 21.25 | 1.07 | 6.19 | 4.10 | 28.86 |
PAT Growth(%) | 20.45 | -2.40 | 5.38 | 13.55 | 28.70 |
EPS Growth(%) | 19.72 | -2.41 | 5.28 | 13.52 | -35.87 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.33 | 0.50 | 0.41 | 0.36 | 0.69 |
Current Ratio(x) | 1.44 | 1.28 | 1.41 | 1.39 | 1.31 |
Quick Ratio(x) | 0.77 | 0.67 | 0.73 | 0.74 | 0.80 |
Interest Cover(x) | 13.32 | 12.76 | 42.66 | 46.80 | 11.69 |
Total Debt/Mcap(x) | 0.23 | 0.15 | 0.15 | 0.09 | 0.12 |